These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32917545)

  • 1. Comment to "Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease".
    Barreiro de Acosta M; Katsanos KH
    Dig Liver Dis; 2020 Nov; 52(11):1302-1303. PubMed ID: 32917545
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
    Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease.
    Macaluso FS; Leone S; Previtali E; Ventimiglia M; Armuzzi A; Orlando A;
    Dig Liver Dis; 2020 Nov; 52(11):1304-1309. PubMed ID: 32807691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD).
    Viscido A; Buda A; Caprioli F; Principi M; Daperno M; Armuzzi A
    Dig Liver Dis; 2020 Aug; 52(8):928-930. PubMed ID: 32616462
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
    Annese V; Vecchi M;
    Dig Liver Dis; 2014 Nov; 46(11):963-8. PubMed ID: 25139379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases.
    Felice C; Pugliese D; Armuzzi A
    Expert Opin Biol Ther; 2019 Oct; 19(10):967-969. PubMed ID: 30616459
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.
    Fiorino G; Girolomoni G; Lapadula G; Orlando A; Danese S; Olivieri I;
    Autoimmun Rev; 2014 Jul; 13(7):751-5. PubMed ID: 24657898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.
    Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A
    Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biosimilars in inflammatory bowel disease].
    Siegmund B; Atreya R; Bokemeyer B; Kruis W; Mudter J; Sander C; Schreiber S; Reindl W; Zeissig S; Kucharzik T
    Z Gastroenterol; 2016 Nov; 54(11):1217-1222. PubMed ID: 27711946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?].
    Schreiber S
    Z Rheumatol; 2015 Oct; 74(8):689-94. PubMed ID: 26450434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab biosimilar in inflammatory bowel disease.
    Fiorino G; Allocca M; Danese S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):775-776. PubMed ID: 34388361
    [No Abstract]   [Full Text] [Related]  

  • 16. The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease.
    Pineles D; Malter L; Liang PS; Arsuaga A; Bosworth B; Hudesman DP; Chang S
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1361-1362. PubMed ID: 29855655
    [No Abstract]   [Full Text] [Related]  

  • 17. Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
    Argüelles Arias F; Hinojosa Del Val J; Vera Mendoza I
    Rev Esp Enferm Dig; 2018 Jun; 110(6):407. PubMed ID: 29527903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
    Danese S; Fiorino G; Raine T; Ferrante M; Kemp K; Kierkus J; Lakatos PL; Mantzaris G; van der Woude J; Panes J; Peyrin-Biroulet L
    J Crohns Colitis; 2017 Jan; 11(1):26-34. PubMed ID: 27927718
    [No Abstract]   [Full Text] [Related]  

  • 19. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biosimilar road in inflammatory bowel disease: the right way?
    Fiorino G; Danese S
    Best Pract Res Clin Gastroenterol; 2014 Jun; 28(3):465-71. PubMed ID: 24913385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.